

Table SI. Cohort characteristics of the patients with cutaneous T-cell lymphomas (CTCLs), cutaneous B-cell lymphomas (CBCLs) and benign cutaneous lymphoid infiltrates (BCLI) included in the study

Diagnosis	CTCLs (n = 114)	CBCLs (n = 35)	BCLI (n = 180)
Age at diagnosis, years, median (range)	54 (8–85)	60 (21–97)	62 (0–92)
Sex, male/female, n	72/42	17/18	115/65
EORTC/ISCL staging system ^a			
T1	50	23	
T2	33	9	
T3	22	3	
T4	9		
Skin biopsies, n	290	70	249
Clonality in skin, n (%)	102 (89.5)	35 (100)	36 (20)
Blood samples, n	203	43	92
Clonality in blood, n/N (%)	59/95 (62.1)	6/28 (21.4)	30/56 (53.6)
Identical clone in skin and blood, n (%)	15 (15.8)	0	2 (3.6)
Status at the last follow-up, n (%)			
ANED	24 (21.1)	24 (68.6)	97(53.9)
AWD	56 (49.1)	5 (14.3)	54 (30)
DOD	16 (14.0)	1 (2.9)	0
DOC	18 (15.8)	5 (14.3)	29 (16.1)
Total follow-up time, months, median (range)	75.2 (1.2–311.2)	81.9 (1.8–376.8)	45.9 (0.03–249.1)

^aStaging system according to Olsen et al. (45) and Kim et al. (46).

ANED: alive with no evidence of disease; AWD: alive with disease; DOC: died of other causes; DOD: died of disease; EORTC/ISCL: European Organization for the Research and Treatment of Cancer and International Society for Cutaneous Lymphomas.